TBC1D3B: A Potential Drug Target and Biomarker (G414059)

Target Name: TBC1D3B

NCBI ID: G414059

TBC1D3B

TBC1D3B: A Potential Drug Target and Biomarker

Tumor suppressor genes (TSGs) are important regulators of cancer growth and progression. TSGs are usually expressed in low levels and are often mutated or deleted in cancer cells. However, their loss or dysfunction can promote tumorigenesis and contribute to cancer outcomes. Oncogenes, which are genes that promote cancer growth and progression, have been identified as potential drug targets.

One potential drug target is TBC1D3B, which is a gene that encodes a protein known as TBC1D3L. TBC1D3L is a transcription factor that plays a role in regulating gene expression and has been implicated in various cellular processes, including cell growth, differentiation, and the response to stimuli.

Studies have suggested that TBC1D3L may be a promising drug target for cancer. TBC1D3L has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been shown to be involved in the regulation of cellular processes that are often associated with cancer, such as cell adhesion, migration, and invasion.

In addition to its potential as a drug target, TBC1D3L has also been shown to be a potential biomarker for cancer. The expression of TBC1D3L has been shown to be associated with cancer progression and poor prognosis in various types of cancer. For example, studies have shown that high expression of TBC1D3L is associated with poor prognosis in breast cancer and colorectal cancer.

Furthermore, TBC1D3L has also been shown to be involved in the regulation of cellular processes that are often associated with cancer risk, such as the development of metastasis. For example, studies have shown that TBC1D3L plays a role in the regulation of angiogenesis, which is the process by which new blood vessels develop in response to tissue injury or infection.

In conclusion, TBC1D3L is a gene that has potential as a drug target and biomarker for cancer. Its high expression in various types of cancer and its involvement in the regulation of cellular processes that are often associated with cancer make it an attractive target for drug development. Further research is needed to fully understand the role of TBC1D3L in cancer and to develop effective treatments.

Protein Name: TBC1 Domain Family Member 3B

Functions: Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity)

The "TBC1D3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets